Pear Therapeutics- Warrants (01/12/2026) EBIT

Pear Therapeutics- Warrants (01/12/2026) posts a EBIT of $-120M as of December 2022. That compares with $-36M in the prior-year period — down 241.4% year over year. That is below the sector sector average of $-69M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Pear Therapeutics- Warrants (01/12/2026)'s EBIT was $-36M. The latest reading is $-120M — a 241.4% year-over-year decrease (period ending December 2022). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $-69M is typical. Pear Therapeutics- Warrants (01/12/2026)'s $-120M is lower that level. That is roughly 78.7% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Pear Therapeutics- Warrants (01/12/2026)'s financial statement story. At $-120M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PEARW's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $-69M), and (3) consistency with growth and profitability. This page covers the first two; Pear Therapeutics- Warrants (01/12/2026)'s other metric pages and overview cover the third.